OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
 
Home Antibody All anti-MLL antibodies
UltraMAB

Anti-MLL GAT Antibody Polyclonal

Generated by Genomic Immunization

div

Specifications Citations Related Products Product Documents
SKU Description Amount Price Availability*  
TA590838
  • Rabbit Polyclonal KMT2A/MLL Antibody
100ug 325 In Stock
This antibody qualifies for Season of Giving promotion: Earn $50 Amazon gift card (use promo code SPQ12081) or donation to Cancer.org (promo code SPQ12082) with $600 purchase of UltraMAB or TrueMAB. Click for details
Add to Shopping Cart
IHC(1)
ELISA(1)

OriGene Data

ImmunogenDNA immunization. This antibody is specific for the Middle Region of the target protein.
Clone NamePolyclonal IsotypeIgG
Species ReactivityHuman Concentration1.2mg/ml
Guaranteed Application *ELISA, IHC Suggested DilutionsELISA: 1:100-1:2000; IHC: 1:150
Buffer20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0
Purification The fragment used for DNA immunization was expressed in E.coli and the purified protein fragment was used for affinity purification of the antibody.
Note This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT

Reference Data

Target NameHomo sapiens lysine (K)-specific methyltransferase 2A (KMT2A), transcript variant 1
Alternative NameALL-1; CXXC7; HRX; HTRX1; MLL; MLL/GAS7; MLL1; MLL1A; TET1-MLL; TRX1; WDSTS
Database LinkNP_001184033
Entrez Gene 4297 Human
FunctionThe MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 [PubMed 17957188]).[supplied by OMIM]
Related PathwayDruggable Genome

* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.

ELISA Image
ELISA: KMT2A / MLL Antibody
IHC Image
Immunohistochemical staining of human colon shows moderate cytoplasmic and nuclear positivity in glandular cells.This validation was performed by Protein Atlas and the presentation of data is for informational purposes only.

 

spacer
Inc 5000 Healthcare Company Copyright © 2014 OriGene Technologies, Inc. All Rights Reserved. Legal Notices.
9620 Medical Center Dr., Suite 200, Rockville, MD 20850 • 1.888.267.4436

Reproduction of any materials from this website is strictly forbidden without permission.

All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title